16.96
price up icon9.70%   1.50
after-market Handel nachbörslich: 17.04 0.08 +0.47%
loading
Schlusskurs vom Vortag:
$15.46
Offen:
$15.48
24-Stunden-Volumen:
2.11M
Relative Volume:
0.74
Marktkapitalisierung:
$783.57M
Einnahmen:
$82.71M
Nettoeinkommen (Verlust:
$-102.24M
KGV:
-4.6213
EPS:
-3.67
Netto-Cashflow:
$-76.57M
1W Leistung:
+20.80%
1M Leistung:
+15.77%
6M Leistung:
+68.76%
1J Leistung:
+4.69%
1-Tages-Spanne:
Value
$15.35
$17.28
1-Wochen-Bereich:
Value
$14.00
$17.28
52-Wochen-Spanne:
Value
$3.42
$17.28

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
Firmenname
Urogen Pharma Ltd
Name
Telefon
972 9 770 7601
Name
Adresse
9 HA'TA'ASIYA ST, RA'ANANA
Name
Mitarbeiter
234
Name
Twitter
@UroGenPharma
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
URGN's Discussions on Twitter

Vergleichen Sie URGN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
URGN
Urogen Pharma Ltd
16.96 648.67M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-16 Hochstufung H.C. Wainwright Neutral → Buy
2025-05-22 Herabstufung H.C. Wainwright Buy → Neutral
2025-04-16 Eingeleitet Scotiabank Sector Outperform
2025-02-19 Fortgesetzt Ladenburg Thalmann Buy
2024-08-22 Eingeleitet Guggenheim Buy
2023-02-08 Herabstufung Jefferies Buy → Hold
2022-04-27 Eingeleitet Berenberg Buy
2020-04-16 Bestätigt H.C. Wainwright Buy
2020-04-13 Bestätigt H.C. Wainwright Buy
2020-01-09 Eingeleitet National Securities Neutral
2019-05-30 Eingeleitet JP Morgan Neutral
2019-05-29 Eingeleitet Goldman Neutral
2019-01-29 Eingeleitet H.C. Wainwright Buy
2018-11-08 Fortgesetzt Jefferies Buy
2018-04-04 Hochstufung Raymond James Mkt Perform → Outperform
2018-01-02 Eingeleitet Ladenburg Thalmann Buy
2017-11-15 Bestätigt Oppenheimer Outperform
2017-11-15 Herabstufung Raymond James Outperform → Mkt Perform
Alle ansehen

Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about UroGen Pharma Ltd. stockSuperior portfolio returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives UroGen Pharma Ltd. stock priceSuperior returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Ltd. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan

Jul 21, 2025
pulisher
Jul 20, 2025

Is UroGen Pharma Ltd. a good long term investmentFree Stock Selection - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse

Jul 20, 2025
pulisher
Jul 19, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire

Jul 19, 2025
pulisher
Jul 19, 2025

Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World

Jul 19, 2025
pulisher
Jul 18, 2025

UroGen Bets Big On Gel-Based Cancer Treatments - Finimize

Jul 18, 2025
pulisher
Jul 17, 2025

URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 17, 2025
pulisher
Jul 16, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View

Jul 16, 2025
pulisher
Jul 15, 2025

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru

Jul 15, 2025
pulisher
Jul 14, 2025

2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse

Jul 14, 2025
pulisher
Jul 13, 2025

What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛

Jul 13, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire

Jul 12, 2025
pulisher
Jul 12, 2025

Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire

Jul 11, 2025
pulisher
Jul 09, 2025

UroGen bladder cancer drug mitomycin wins FDA approval - MSN

Jul 09, 2025
pulisher
Jul 09, 2025

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛

Jul 09, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress - Investing.com India

Jul 08, 2025
pulisher
Jul 08, 2025

UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer - Yahoo Finance

Jul 08, 2025
pulisher
Jul 07, 2025

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Jul 07, 2025
pulisher
Jul 07, 2025

URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com India

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock New - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen completes enrollment in phase 3 bladder cancer trial - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

UroGen Pharma Completes Patient Enrollment in Phase 3 UTOPIA Trial for UGN-103 in Bladder Cancer Treatment - Quiver Quantitative

Jul 07, 2025

Finanzdaten der Urogen Pharma Ltd-Aktie (URGN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):